DiviTum TKa blood test measures thymidine kinase activity which reflects cell proliferation. Divitum TKa is a test used by oncologists.

DiviTum® TKa is a blood-based biomarker test that monitors and predicts treatment response in hormone receptor-positive metastatic breast cancer. The test measures thymidine kinase activity (TKa) which reflects cell proliferation.

 

 

Clinical Evidence
About The Test

Biovica is a Swedish biotech company founded in 2009, committed to developing and commercializing novel blood-based biomarker assays. Our initial focus is breast cancer, a disease responsible for over 685,000 deaths a year (BCRF, 2022). We work with leading cancer institutes, collaborative groups, and pharmaceutical companies on product development with the aim of improving outcomes and lowering costs.

About Biovica
SOTA picture

Event Calendar

See our events

Take a look at our Event Calendar. Meet us at upcoming conferences and schedule a meeting with us for the events.

Event Calendar

Next-level mBC Monitoring

DiviTum® TKa is an innovative tumor TK activity (TKa) profile test for early prognosis and prediction of metastatic breast cancer treatment outcomes in postmenopausal HR+ mBC patients.1-4

References:

1. Bergqvist M, et al. Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226). Biomarkers. Vol 28, 2023: 313-322.

2. Paoletti C, et al. Evaluating serum thymidine kinase 1 in patients with hormone receptor-positive metastatic breast cancer receiving first-line endocrine therapy in the SWOG S0226 trial. Clin Cancer Res. 2021;27(22):6115-6123.

3. Malorni L, et al. International Breast Cancer Study Group; Breast International Group and PYTHIA Collaborators. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. Eur J Cancer. 2022;164:39-51.

4. Malorni L, et al. Serum thymidine kinase activity in patients with HRpositive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial. Eur J Cancer. 2023; 186: 1–11. Eur J Cancer 2023; 186: 1–11.

metastatic cells dividing

TKa as a Biomarker

Learn more about what makes TKa an important oncology biomarker.

The Science Behind TKa
Anders
I am certain that the DiviTum TKa test will improve the care for many cancer patients.
Anders Rylander
CEO - Biovica
Lightbulb for side image

PLEASE SELECT ONE

Please specify your home location

USA
Europe/Rest of World